Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.48 |
| ▸ | NPY1R | P25929 | 7/20 | 0.48 |
| ▸ | NPY2R | P49146 | 5/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.45 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 3/20 | 0.41 |
| ▸ | FNTB | P49356 | 3/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576035 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL1119077 | 0.97 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL5357516 | 0.97 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL1711701 | 0.88 | GNPAT (0.52) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29540393 | 0.88 | GNPAT (0.52) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL5966594 | 0.88 | GNPAT (0.52) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL5966602 | 0.88 | GNPAT (0.52) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL1711691 | 0.88 | GNPAT (0.52) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL7785244 | 0.88 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL7292029 | 0.88 | GNPAT (0.52) | NPY4RNPY1RNPY2RNPY5RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7164002-B2 | FVIIa antagonists | GENENTECH, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20040087767-A1 | FVIIa antagonists | GENENTECH, INC. | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087767-A1 | FVIIa antagonists | F13B, F5, TFPI | NPY4R 1270/4885NPY1R 956/4885NPY2R 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.